Camden GPs from CHE GP Federation are supporting two clinical trials testing long-acting antibody combination treatment to protect against Covid-19.
One trial (STORMCHASER) is looking at post-exposure prophylaxis and is recruiting asymptomatic adults in very recent contact with a positive Covid case. The second trial (PROVENT) is looking at pre-exposure prophylaxis by offering the antibodies to people in residential institutions and with underlying chronic illness or immunosuppression who are at high risk of not responding to a vaccine.
NCL GPs can use the information links below to offer participation in these trials to their patients.
The trials are run by University College London Hospital and involve an antibody synthesised by AstraZeneca. These are world-leading novel therapeutic trials that are taking place on our doorstep and UCLH made recent headlines when it achieved a world first in recruiting participants into a Covid antibody trial.
The trials will be supported by CHE GP Federation led by Dr Harpreet Sood and Federation chair, Dr Daniel Beck. GP practices are supporting recruitment and a clinical team has been created to provide monitoring and surveillance of trial participants during the studies.
Dr Sood said:
“We are excited to bring access to these studies to our local population and use our excellent clinical workforce to support the trials. Our intention is that this is the first of many such partnerships.”
This partnership provides a new and unique collaboration between UCLH and local GPs, supporting effective rapid recruitment and efficient running of both studies.
For more information on the trials, please visit: